🚀 ProPicks AI Hits +34.9% Return!Read Now

These Analysts Boost Price Targets On Biogen Following Positive Alzheimer's Drug Data, Shares Jump

Published 28/09/2022, 14:54
© Reuters These Analysts Boost Price Targets On Biogen Following Positive Alzheimer's Drug Data, Shares Jump
BIIB
-
TGTB34
-
BIIB34
-

Biogen, Inc. (NASDAQ: NASDAQ:BIIB) shares jumped sharply on Wednesday.

The stock was reacting to a positive late-stage readout for the company’s anti-amyloid antibody treatment candidate for slowing the progression of Alzheimer’s disease. Lecanemab, the investigational treatment, met the primary endpoint and all key secondary endpoints with highly statistically significant results, the company said in a statement.

Biogen shares climbed 38.3% to trade at $273.53 on Wednesday.

These analysts made changes to their price targets on Biogen following the release of data.

  • Mizuho raised price target on Biogen from $207 to $270. Mizuho analyst Salim Syed upgraded the stock from Neutral to Buy.
  • BMO Capital boosted Biogen price target from $217 to $360. BMO Capital analyst Evan Seigerman upgraded the stock from Market Perform to Outperform.
  • Baird raised Biogen price target from $224 to $340. Baird analyst Brian Skorney upgraded the stock from Neutral to Outperform.
  • Piper Sandler boosted price target on the stock from $200 to $280. Piper Sandler analyst Christopher Raymond maintained Biogen with a Neutral.
  • RBC Capital raised the price target on the stock from $251 to $321. RBC Capital analyst Brian Abrahams maintained the stock with an Outperform.
  • Wells Fargo (NYSE:WFC) boosted Biogen’s price target from $265 to $350. Wells Fargo analyst Mohit Bansal maintained an Overweight rating on the stock.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.